Larson John, Rich Lucas, Deshmukh Amrish, Judge Erin C, Liang Jackson J
Division of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, MI 48109, USA.
J Clin Med. 2022 Jun 6;11(11):3233. doi: 10.3390/jcm11113233.
Ventricular arrhythmias (Vas) are a life-threatening condition and preventable cause of sudden cardiac death (SCD). With the increased utilization of implantable cardiac defibrillators (ICD), the focus of VA management has shifted toward reduction of morbidity from VAs and ICD therapies. Anti-arrhythmic drugs (AADs) can be an important adjunct therapy in the treatment of recurrent VAs. In the treatment of VAs secondary to structural heart disease, amiodarone remains the most well studied and current guideline-directed pharmacologic therapy. Beta blockers also serve as an important adjunct and are a largely underutilized medication with strong evidentiary support. In patients with defined syndromes in structurally normal hearts, AADs can offer tailored therapies in prevention of SCD and improvement in quality of life. Further clinical trials are warranted to investigate the role of newer therapeutic options and for the direct comparison of established AADs.
室性心律失常（Vas）是一种危及生命的状况，也是心脏性猝死（SCD）的可预防原因。随着植入式心脏除颤器（ICD）使用的增加，室性心律失常管理的重点已转向降低室性心律失常和ICD治疗的发病率。抗心律失常药物（AADs）可以是治疗复发性室性心律失常的重要辅助治疗方法。在治疗继发于结构性心脏病的室性心律失常时，胺碘酮仍然是研究最充分且目前指南指导的药物治疗。β受体阻滞剂也是一种重要的辅助药物，并且在很大程度上未得到充分利用，但有强有力的证据支持。在结构正常心脏中有明确综合征的患者中，抗心律失常药物可以提供针对性的治疗，以预防心脏性猝死并改善生活质量。有必要进行进一步的临床试验，以研究更新的治疗选择的作用以及对已确立的抗心律失常药物进行直接比较。
